Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Treatment-resistant depression

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    59 result(s) found for: Treatment-resistant depression. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-001637-27 Sponsor Protocol Number: LQD Start Date*: 2016-09-20
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
    Medical condition: Treatment resistant major depressive disorder (single episode or recurrent). Treatment resistant depression, defined as failure to respond to two or more adequate doses of antidepressant in the cur...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10067373 Depression perimenopausal LLT
    21.1 10037175 - Psychiatric disorders 10066555 Chronic depression LLT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012391 Depression postpartum (excl psychosis) LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10012390 Depression postoperative PT
    20.0 10037175 - Psychiatric disorders 10012386 Depression mental LLT
    21.1 10037175 - Psychiatric disorders 10066530 Acute depression LLT
    20.0 10037175 - Psychiatric disorders 10012389 Depression postmenopausal LLT
    20.0 10037175 - Psychiatric disorders 10012387 Depression NOS LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    21.1 10037175 - Psychiatric disorders 10037998 Reactive depression LLT
    21.1 10037175 - Psychiatric disorders 10042457 Suicidal depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-004172-17 Sponsor Protocol Number: ETES Start Date*: 2021-04-26
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Electroconvulsive therapy vs. esketamine nasal spray in treatment-resistant depression: a longitudinal, randomized efficacy comparison pilot study
    Medical condition: treatment resistant depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005457-25 Sponsor Protocol Number: PCN-101-21 Start Date*: 2021-08-30
    Sponsor Name:Perception Neuroscience, Inc
    Full Title: A randomized, placebo-controlled, double-blind study to assess the safety and efficacy of intravenous PCN-101 in treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000090-23 Sponsor Protocol Number: UoB1651 Start Date*: 2013-06-19
    Sponsor Name:University of Bristol
    Full Title: Mirtazapine added to SSRIs for treatment resistant depression in primary care: a placebo controlled randomised controlled trial
    Medical condition: Treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004873 10045543 Unipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006089-40 Sponsor Protocol Number: 2006TUDOR_01 Start Date*: 2007-03-20
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: High dose corticosteroid pulses in treatment-resistant depression : a randomized double-blind placebo-controlled pilot study
    Medical condition: Resistant depression
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012378 Depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004857-14 Sponsor Protocol Number: 1 Start Date*: 2009-05-29
    Sponsor Name:Psykiatrisk Center Rigshospitalet
    Full Title: The effects of erythropoietin on depressive symptoms and neurocognitive deficits in patients with treatment resistant depression and in patients with remitted bipolar disorder – a proof of concept ...
    Medical condition: Treatment resistant depression and bipolar disorder in remission.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050648 Blood erythropoietin LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003002-12 Sponsor Protocol Number: CMIJ821X2201 Start Date*: 2019-04-08
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A multi-center, randomized, subject and investigator-blinded, placebo-controlled, active comparator, parallel-group proof of concept study to evaluate the efficacy, safety, tolerability, and pharma...
    Medical condition: Treatment Resistant Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-011409-17 Sponsor Protocol Number: LAST-RD - FARM77Z3BL Start Date*: 2009-10-01
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
    Full Title: Randomized evaluation of the effectiveness of lithium in subjects with treatment-resistant depression and suicide risk. An independent, pragmatic, multicentre, parallel-group, superiority trial.
    Medical condition: Treatment-resistant depression and suicide risk.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012397 Depression suicidal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006510-36 Sponsor Protocol Number: NL79264.091.21 Start Date*: 2021-12-21
    Sponsor Name:Radboudumc
    Full Title: Exploring the Pharmacomicrobiomics of Depression
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004208-20 Sponsor Protocol Number: GH001-MDD-102 Start Date*: 2019-08-21
    Sponsor Name:Gh Research Limited
    Full Title: A phase 1/2 study of GH001 in patients with treatment-resistant depression
    Medical condition: Treatment-resistant depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    21.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002577-22 Sponsor Protocol Number: COMP003 Start Date*: Information not available in EudraCT
    Sponsor Name:COMPASS Pathfinder, Limited
    Full Title: The safety and efficacy of psilocybin as an adjunctive therapy in participants with treatment-resistant depression
    Medical condition: treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001217-17 Sponsor Protocol Number: Max-Planck-Institute of Psychiatry Start Date*: 2005-09-12
    Sponsor Name:Max-Planck-Institute of Psychiatry
    Full Title: Comparison of venlafaxine augmentation with lamotrigine, quetiapine, or placebo in treatment resistant depression
    Medical condition: Treatment resistant depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003288-36 Sponsor Protocol Number: COMP001 Start Date*: 2018-03-09
    Sponsor Name:COMPASS Pathways, Ltd
    Full Title: The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)
    Medical condition: Treatment-Resistant Depression (P-TRD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    21.1 100000004873 10025463 Major depressive disorder, single episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) PT (Completed) NL (Completed) IE (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002160-24 Sponsor Protocol Number: BP25712 Start Date*: 2012-04-12
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of RO4995819 Versus Placebo, as Adjunctive Therapy in Patients with Major D...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    14.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2022-000574-26 Sponsor Protocol Number: GH001-TRD-201 Start Date*: 2022-11-25
    Sponsor Name:GH Research Ireland Limited
    Full Title: A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in patients with treatment-resistant depression
    Medical condition: Treatment-resistant depression (TRD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000778-71 Sponsor Protocol Number: CN162-007 Start Date*: 2011-11-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depress...
    Medical condition: Subjects with Treatment Resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003984-24 Sponsor Protocol Number: EPIsoDE_01 Start Date*: 2020-11-17
    Sponsor Name:Central Institute of Mental Health
    Full Title: A phase II randomized, double-blind, active placebo-controlled parallel group trial to examine the efficacy and safety of psilocybin in treatment-resistant major depression
    Medical condition: Treatment-Resistant Depressive Episode or Treatment-Resistant Recurrent Depressive Disorder of moderate to severe degree withoutpsychotic features
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024371-12 Sponsor Protocol Number: CN162-010 Start Date*: 2011-11-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A multicenter, Double-blind 58 week Rollover Study to assess the Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression.
    Medical condition: Subjects with Treatment Resistant Major Depression
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) SE (Completed) FI (Prematurely Ended) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002232-16 Sponsor Protocol Number: TAK-653-2001 Start Date*: 2017-12-15
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects with Treatment-Resistant Depression
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023414-31 Sponsor Protocol Number: MD-KPSY-01/10 Start Date*: 2012-03-05
    Sponsor Name:Medizinische Fakultät. Otto von Guericke Universität
    Full Title: Ketamine in treatment resistant major depression (TRD)
    Medical condition: Therapy resistant depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 13:52:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA